Fructooligosaccharide ameliorates inflammation-induced chronic pain via deactivation of LPS/TLR-4/NF-κB p65/TNF-α/IL-6 pathway in estrogen-deficient rats

Key Points

• Chronic pain mitigation occurs through pathway deactivation, revealing a promising intervention.
• Key measures show significant decrease in TNF-α and IL-6 levels following treatment with fructooligosaccharide.
• Assessment using estrogen-deficient rat models demonstrates an effective method to explore chronic pain mechanisms.
• This study highlights potential therapeutic applications and warrants further exploration in human studies.